Invitrogen

SIGLEC15 Polyclonal Antibody

4个已发表图片

3 篇参考文献

查看其他8个SIGLEC15抗体

抗体检测数据 (1)
已发表图片 (4)

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

图: 1 / 5

SIGLEC15 Antibody (PA5-50759) in IHC (P)

Immunohistochemical analysis of SIGLEC15 inparaffin-embedded Human liver cancer tissue using SIGLEC15 Polyclonal Antibody (Product # PA5-50759) at a 1:50 dilution. (Original magnification: x200).

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF)

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF)

SIGLEC15 Antibody in Western Blot, Immunohistochemistry (WB, IHC)

SIGLEC15 Antibody in Western Blot (WB)

Product Image Gallery

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Immunohistochemical analysis of SIGLEC15 inparaffin-embedded Human liver cancer tissue using SIGLEC15 Polyclonal Antibody (Product # PA5-50759) at a 1:50 dilution. (Original magnification: x200).

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF) — 4 FIGURE Siglec-15 was a direct target of miR-7109 in clear-cell renal cell carcinoma (ccRCC). (A) Real-time PCR analysis of miR-7109 expression in ccRCC tumor samples with paired adjacent normal tissues. (B) Correlation analysis between miR-7109 and Siglec-15 in ccRCC tissue samples (n = 100). (C) Change of miR-7109 expression in both A704 and A498 cells in response to miR-7109 inhibitor. (D) Change of miR-7109 expression in both 769-p and Caki-1 cells in response to miR-7109 mimic. (E) Endogenous Siglec-15 transcripts were quantified in both A704 and A498 cells transfected with either control or miR-7109 inhibitor. (F) Endogenous Siglec-15 transcripts were quantified in both 769-p and Caki-1 cells transfected with either control or miR-7109 mimics. (G) Western blot analysis of Siglec-15 proteins in the same cells as in panel E and F. (H) Flow cytometry analysis of cell surface Siglec-15 abundance in A704 and A498 cells in response to miR-7109 inhibitor. (I) Flow cytometry analysis of cell surface Siglec-15 abundance in 769-p and Caki-1 cells in response to miR-7109 mimics. (J) Immunofluorescence staining of cell surface Siglec-15 in A498 cells transfected with either control or miR-7109 inhibitor. (K) Alignment between miR-7109 seed region and both wild-type and putative binding site-mutated Siglec-15 3'UTR. (L) Luciferase reporter analysis of the potential regulatory effects of miR-7109 on Siglec-15 in 293T cells, which were transfected with control, miR-7109 mimics, and m

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF) — 3 FIGURE LINC00973-upregulated Siglec-15 was dependent on miR-7109. (A) Real-time PCR analysis of endogenous miR-7109 in LINC00973-deficient 769-p and Caki-1 cells in response to either negative control or miR-7109 inhibitor. (B) Real-time PCR analysis of endogenous miR-7109 in LINC00973-proficient A704 and A498 cells in response to either control or miR-7901 mimic. (C) Quantitative analysis of Siglec-15 transcript in LINC00973 intact or depleted 769-p and Caki-1 cells treated with control or miR-7109 inhibitor. (D) Quantitative analysis of Siglec-15 transcript in LINC00973 naive or overexpressing A704 and A498 cells treated with control or miR-7109 mimics. (E) Western blot results of Siglec-15 protein in the cells as described in C and D. (F) Immunofluorescence staining of cell surface Siglec-15 in A498 cells expressing either naive or ectopic LINC00973, and transfected with either control or miR-7109 mimics. (G, H) Flow cytometry analysis of cell surface abundance of Siglec-15 in cells as specified in panel E

SIGLEC15 Antibody in Western Blot, Immunohistochemistry (WB, IHC) — 2 FIGURE LINC00973 upregulated Siglec-15 in clear-cell renal cell carcinoma (ccRCC) cells. (A) Comparison of LINC00973 abundance in Siglec-15 negative and positive ccRCC tumors. (B) Representative images of Siglec-15 immunohistochemistry (IHC) staining results. (C) Correlation analysis of endogenous LINC00973 and Siglec-15 expression in publicly available TCGA kidney cells (n = 34). (D) Correlation analysis of LINC00973 and Siglec-15 in clinical ccRCC tumor samples (n = 100). (E) Establishment of LINC00973-knockdown cell lines in 769-p and Caki-1 cells was validated by real-time PCR. (F) Establishment of LINC00973-overexpressing cell lines in A704 and A498 cells was validated by real-time PCR. (G) Relative expression of Siglec-15 transcripts in LINC00973-deficient 769-p and Caki-1 cells. (H). Relative expression of Siglec-15 transcripts in LINC00973-proficient A704 and A498 cells. (I) Western blot analysis of Siglec-15 protein in LINC00973 knockdown or overexpressing cells. Flow cytometry analysis of cell surface Siglec-15 abundance in response to LINC00973 knockdown in 769-p (J) and Caki-1 (K) cells, and LINC00973-overexpressing in A704 (L) and A498 (M). N. Immunofluorescence staining of cell surface Siglec-15 of A498 in response to either control (NC) or LINC00973 overexpression

SIGLEC15 Antibody in Western Blot (WB) — 6 FIGURE LINC00973-miR-7109-Siglec-15 axis involved in immune activations in clear-cell renal cell carcinoma (ccRCC) cells. (A) Establishment of Siglec-15 overexpression cells in A704 and A498 was confirmed by real-time PCR. (B) Establishment of Siglec-15 knockdown cells in 769-p and Caki-1 cells was confirmed by real-time PCR. (C) Western blot results of relative expression of Siglec-15 protein in cells described in (A) and (B). (D) Interleukin-2 (IL-2) production analysis in Jurkat: A704/A498 (EV or Siglec-15, 2:1) co-culture system. IL-2 was quantified with an ELISA kit at 48 and 72 h, respectively. (E) IL-2 production analysis in Jurkat: 769-p/Caki-1 (shNT or shSiglec-15, 2:1) co-culture system. (F) IL-2 production analysis of Jurkat co-culture system with both A704 and A498 cells transfected with control or LINC00973 in combination with either miR-NC or miR7109 mimics. (G) IL-2 production analysis of Jurkat co-culture system with both 769-p and Caki-1 cells transfected with negative control or shLINC0973 in combination with either miR-NC or miR-7109 inhibitor. (H) Tumor necrosis factor-alpha (TNF-alpha) secretion analysis of Jurkat co-culture system with both A704 and A498 cells transfected with control or LINC00973 in combination with either miR-NC or miR-7109 mimics. (I) TNF-alpha secretion analysis of Jurkat co-culture system with both 769-p and Caki-1 cells transfected with either negative control or shLINC00973 in combination with either miR-NC or miR-7109 inhibitor

产品信息

PA5-50759

应用

建议稀释比

已发表文章

免疫印迹 (WB)

1:500-1:2,000

查看1篇已发表文章 1篇已发表文章

免疫组化 (IHC)

-

查看1篇已发表文章 1篇已发表文章

免疫组化（石蜡） (IHC (P))

1:50-1:200

-

免疫细胞化学 (ICC/IF)

-

查看1篇已发表文章 1篇已发表文章

产品规格

种属反应

Human, Mouse

已发表种属

Human

宿主/亚型

Rabbit / IgG

分类

Polyclonal

类型

Antibody

抗原

Synthetic peptide corresponding to a region derived from internal residues of human sialic acid binding Ig-like lectin 15

偶联物

Unconjugated Unconjugated Unconjugated

形式

Liquid

浓度

0.9 mg/mL

纯化类型

Antigen affinity chromatography

保存液

PBS, pH 7.4, with 40% glycerol

内含物

0.05% sodium azide

保存条件

-20°C

运输条件

Wet ice

AB_2636211

产品详细信息

The antibody detects endogenous levels of total SIGLEC15 protein.

靶标信息

Binds sialylated glycoproteins.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

Product References

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

PA5-50759 was used in Western Blot, Immunocytochemistry to highlight the importance of LINC00973-miR-7109-Siglec-15 in immune evasion in ccRCC, which offers significant opportunity for both therapeutic intervention and diagnostic/prognostic exploitations.

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

PA5-50759 was used in Western Blot, Immunocytochemistry to highlight the importance of LINC00973-miR-7109-Siglec-15 in immune evasion in ccRCC, which offers significant opportunity for both therapeutic intervention and diagnostic/prognostic exploitations.

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

PA5-50759 was used in Western Blot, Immunocytochemistry to highlight the importance of LINC00973-miR-7109-Siglec-15 in immune evasion in ccRCC, which offers significant opportunity for both therapeutic intervention and diagnostic/prognostic exploitations.

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

PA5-50759 was used in Western Blot, Immunocytochemistry to highlight the importance of LINC00973-miR-7109-Siglec-15 in immune evasion in ccRCC, which offers significant opportunity for both therapeutic intervention and diagnostic/prognostic exploitations.

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

PA5-50759 was used in Western Blot, Immunocytochemistry to highlight the importance of LINC00973-miR-7109-Siglec-15 in immune evasion in ccRCC, which offers significant opportunity for both therapeutic intervention and diagnostic/prognostic exploitations.

Thu Oct 01 00:00:00 UTC 2020

生物信息学

蛋白别名: CD33 antigen-like 3; CD33 molecule-like 3; sialic acid binding Ig-like lectin 15; Sialic acid-binding Ig-like lectin 15; Siglec; Siglec 15; Siglec-15

查看更多收起

基因别名: CD33L3; EG620235; HsT1361; SIGLEC-15; SIGLEC-I; SIGLEC15

查看更多收起

UniProt ID: (Human) Q6ZMC9

查看更多收起

Entrez Gene ID: (Human) 284266, (Mouse) 620235

查看更多收起

protein binding

regulation of actin cytoskeleton organization innate immune response regulation of bone resorption cellular response to lipoprotein particle stimulus regulation of osteoclast development